Stock-based Compensation - Narrative (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	May 31, 2023 shares	Mar. 31, 2026 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) shares	Dec. 31, 2025 USD ($)
Share-Based Payment Arrangement
Stock-based compensation expense (income)		$ (3,915)	$ 27,642
Accrued stock-based compensation		2,723		$ 8,256
Performance Shares
Share-Based Payment Arrangement
Stock-based compensation expense (income)		(3,900)
Accrued stock-based compensation		$ 2,700		$ 8,300
Change in accrued stock based compensation			$ 27,600
RSUs
Share-Based Payment Arrangement
Share-based award vesting period		1 year 9 months 18 days	1 year 10 months 24 days
Unrecognized compensation cost		$ 5,500	$ 2,900
Clinigence Holdings, Inc.
Share-Based Payment Arrangement
Conversion ratio		357.14286%
Equity Incentive 2022 Plan
Share-Based Payment Arrangement
Share-based award vesting period		24 months
Multiplying factor		10
Equity Incentive 2022 Plan | Prior to the reverse stock split
Share-Based Payment Arrangement
Share price (in dollars per share) | $ / shares		$ 420.00
2023 Employee Stock Purchase Plan
Share-Based Payment Arrangement
Shares authorized (in shares) | shares	33,333
Percentage of the market value at which employee stock purchase plan participants are entitled to purchase stock under the plan	85.00%
Common stock issued for employee stock purchase plan (in shares) | shares		547	1,161